This study, conducted at a single center in Wuhan, China, aimed to describe the clinical characteristics, laboratory features, treatment, and outcomes of acute cerebrovascular disease (CVD) in patients with COVID-19. Among 219 patients with confirmed COVID-19, 10 (4.6%) developed acute ischemic stroke, and 1 (0.5%) had intracerebral hemorrhage. Patients with new-onset CVD were significantly older (75.7±10.8 years vs 52.1±15.3 years, p<0.001) and more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01). They also had a higher prevalence of cardiovascular risk factors, including hypertension, diabetes, and a history of CVD. These patients exhibited increased inflammatory responses and a hypercoagulable state, as evidenced by elevated C-reactive protein (CRP) and D-dimer levels. The mortality rate among patients with CVD was 54.5%. The study concluded that acute CVD is not uncommon in COVID-19 and that older patients with risk factors are more likely to develop CVD. Further research is needed to identify optimal management strategies for CVD in COVID-19 patients.This study, conducted at a single center in Wuhan, China, aimed to describe the clinical characteristics, laboratory features, treatment, and outcomes of acute cerebrovascular disease (CVD) in patients with COVID-19. Among 219 patients with confirmed COVID-19, 10 (4.6%) developed acute ischemic stroke, and 1 (0.5%) had intracerebral hemorrhage. Patients with new-onset CVD were significantly older (75.7±10.8 years vs 52.1±15.3 years, p<0.001) and more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01). They also had a higher prevalence of cardiovascular risk factors, including hypertension, diabetes, and a history of CVD. These patients exhibited increased inflammatory responses and a hypercoagulable state, as evidenced by elevated C-reactive protein (CRP) and D-dimer levels. The mortality rate among patients with CVD was 54.5%. The study concluded that acute CVD is not uncommon in COVID-19 and that older patients with risk factors are more likely to develop CVD. Further research is needed to identify optimal management strategies for CVD in COVID-19 patients.